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This article contains the recommended immunization schedule by the Committee on Infectious 
Diseases of the Korean Pediatric Society, updated in March 2013, when Haemophilus influenzae 
type b vaccine is now included in the National Immunization Program in Korea. It also includes catch-
up immunization schedule for children and adolescents who are behind the recommended schedule. 
These schedules are a minor revision of the corresponding parts of Immunization Guideline, 7th edition, 
of the Korean Pediatric Society, released in 2012. Pediatricians should be aware of these schedules to 
provide adequate immunization to Korean children and adolescents.
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Introduction
The aim of this article is to introduce the recommended immunization schedule 
for Korean children and adolescents to pediatricians, general practitioners, vaccine 
providers, and other medical personnel or related researchers. The schedule shown here 
is based on the schedule recommended by the Committee on Infectious Diseases of the 
Korean Pediatric Society (KPS), 2012
1), and updated by the committee in March 2013. 
Haemophilus influenzae type b vaccine has been recommended by KPS since 2002 and is 
newly included in the National Immunization Program in Korea this year. A quadrivalent 
meningococcal polysaccharide-protein conjugate vaccine (Menveo, Norvatis, Basel, 
Switzerland), introduced since 2012 is recommended for persons at increased risk for 
meningococcal diseases aged 2 to 55 years and details are described in the corresponding 
chapter of KPS Immunization Guideline, 2012.
Recommended immunization schedule
The schedule shown below (Table 1) is for persons aged 0 to 18 years without delayed 
vaccination. For further KPS guidance on the immunization of each vaccine, refer to each 
of the vaccine chapters of the KPS Immunization Guideline, 2012, and the KPS website http://dx.doi.org/10.3345/kjp.2013.56.6.231
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(http://www.pediatrics.or.kr). Important updates on the guideline 
will be also announced through the KPS newsletters and the KPS 
website.
Catch-up immunization schedule
For children and adolescents whose vaccination has been 
delayed for more than one month, the schedule should be 
referred to the catch-up immunization schedule (Table 2). The 
schedule comprises two parts; for infants and children aged 0 to 
6 years and for children and adolescents aged 7 to 18 years. 
Conclusion
The KPS recommends at present that all children and adoles-
cents in Korea receive vaccination according to the schedules 
provided in this article. Pediatricians should be aware of these 
updated schedules and advise parents and caregivers on the 
proper immunization. 
Table 1. Recommended immunization schedule for children and 
adolescents: the Korean Pediatric Society, 2013
Age Vaccine
Birth HepB
1)
0–4 wk BCG
1 mo HepB
2 mo DTaP, IPV, Hib*
, 2), PCV
†,3), RV
†,4)
4 mo DTaP, IPV, Hib, PCV, RV
6 mo HepB, DTaP, IPV
5), Hib, PCV, RV, IV
6)
12–15 mo MMR
7), Var
8), Hib, PCV
12–23 mo JEV
9), HepA
†,10)
15–18 mo DTaP
4–6 yr DTaP, IPV, MMR
6 yr JEV
11–12 yr Tdap
11), HPV
†,12)
12 yr JEV
BCG, bacille Calmette-Guérin; DTaP, diphtheria and tetanus toxoids and 
acellular pertussis vaccine; HepA, hepatitis A vaccine; HepB, hepatitis B 
vaccine; Hib, Haemophilus influenzae type b vaccine; HPV, human papilloma 
virus vaccine; IPV, inactivated polio vaccine; IV, influenza vaccine; JEV, 
Japanese encephalitis vaccine; MMR, measles, mumps, and rubella vaccine; 
PCV, pneumococcal conjugate vaccine; RV, rotavirus vaccine; Tdap, tetanus 
and diphtheria toxoids and acellular pertussis vaccine; Var, varicella vaccine.
*Hib is now covered by the National Immunization Program of Korea as of 
March 2013. 
†PCV, RV, HepA, and HPV are optional vaccines, which are 
recommended to all children and adolescents, but parents or guardians may 
make decision of administration. 
  1)HepB: Administer HepB at 0, 1, and 6 months of age according to the 
maternal hepatitis B surface antigen (HBsAg) status as follows.
a. If maternal HBsAg is positive, administer HepB and 0.5 mL of hepatitis B 
immune globulin (HBIG) within 12 hours of birth at different sites. 
b. If maternal HBsAg status is unknown, administer HepB within 12 hours of 
birth and test maternal HBsAg status as soon as possible, and if the result 
is positive, administer HBIG as soon as possible, no later than 7 days of 
birth.
c. If maternal HBsAg is negative, start HepB series no later than 2 months of 
age, preferably before hospital discharge. 
  2)Hib: Primary series doses of Hib are at 2, 4, and 6 months of age; however, 
for PRP-OMP, a dose at 6 months is not required if it was administered at 2 
and 4 months of age. Administer a booster dose of Hib at 12–15 months of 
age. 
  3)PCV: Primary series of PCV are at 2, 4, and 6 months of age and a booster 
dose is at 12–15 months of age. If the first dose is administered after 6 
months of age, the total number of doses may vary 1 through 3 according to 
the age of the first dose. 
  4)RV: Administer either Rotarix (GSK) at 2 and 4 months of age or RotaTeq (MSD) 
at 2, 4, and 6 months of age. The first dose of any RV can be administered 
as early as 6 weeks of age but no later than 14 weeks 6 days. The minimal 
interval between any doses is 4 weeks, and the final dose should be 
administered no later than 8 month 0 days for both vaccines.
  5)IPV: The third dose of IPV may be administered at age 6–18 months.
  6)IV: Administer IV every year to all children aged 6–59 months, caregivers and 
family members of children aged 0–59 months, children and adolescents 5 
years and older who have any underlying medical conditions predisposing 
them to influenza infection, their caregivers, and persons who want IV. 
Administer 1 dose to children and adolescents aged 9 years and older; 
administer 2 doses with an interval of 4 weeks or more to children younger 
than 9 years who are receiving IV for the first time and to children younger 
than 9 years who received only the first dose but not the second dose last 
year. If inactivated IV (IIV) is used, administer 0.25 mL of IIV intramuscularly 
to vaccinees aged 6–35 months and 0.5 mL of IIV to those aged 3 years 
and older. Live attenuated IV (LAIV) is approved for persons aged 2 years 
and older; if LAIV is used, administer 0.2 mL of LAIV intranasally. 
  7)MMR: The first dose should be administered at age 12 through 15 
months and the second dose at age 4–6 years. The second dose may be 
administered before age 4 years with an interval 4 weeks or more from 
the first dose. When an outbreak of measles occurs in the community, a 
dose of measles vaccine or measles containing vaccine, such as MMR, can 
be administered to infants aged 6–11 months; these children should be 
revaccinated with 2 doses of MMR, i.e., the first at age 12–15 months, and 
the second at age 4–6 years.
  8)Var: Administer all children a single dose of Var at age 12–15 months. 
Second dose of Var may be administered to children aged 15 months to 12 
years who attend day-care centers, schools, or facilities where chicken pox 
is prevalent, provided at least 3 months have elapsed since the first dose. 
For adolescents aged 13 and older without evidence of immunity, two doses 
of Var are indicated with a minimum interval of 4 weeks.
  9)JEV: Administer either inactivated JEV (IJEV) series or live attenuated JEV 
(LAJEV) series. If IJEV is used, administer the first dose at age 12–23 
months and the second dose 7–30 days later. Administer the third dose of 
IJEV next year with a minimal interval of 6 months from the second dose. 
Administer booster doses, i.e., the fourth and the fifth doses, at ages 6 and 
12 years, respectively. Administer 0.5 mL to children younger than 3 years 
and 1.0 mL to those aged 3 years and older. If LAJEV is used, administer 
the first dose at age 12–23 months and the second dose at least 12 months 
later. 
10)HepA: Administer the first dose to children aged 12 months and older and 
the second dose 6–18 months later according to the instruction of each 
HepA product.
11)Tdap: Administer one dose of Tdap to adolescents aged 11–12 years, and 
administer Tetanus and diphtheria toxoids (Td) 10 years later. To adolescents 
aged 11–18 years with a history of Td but no Tdap, administer one dose of 
Tdap regardless of the interval since the last Td vaccination, and administer 
Td 10 years later.
12)HPV: Administer the first dose of either Cervarix (GSK) or Gardasil (MSD) to 
females aged 11–12 years. Administer the second dose one month (Cervarix) 
or two months (Gardasil) after the first dose and the third dose 6 months 
after the first dose for both vaccines.  233 http://dx.doi.org/10.3345/kjp.2013.56.6.231
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Table 2. Catch-up immunization schedule for children and adolescents: the Korean Pediatric Society, 2013
Vaccine Minimum age 
for dose 1
Minimum interval between doses
Dose 1–2 Dose 2–3 Dose 3–4 Dose 4–5
Children younger than 7 yr who start late or who are more than 1 mo behind
HepB
1) Birth 4 wk 8 wk and at least 16 wk after dose 1
1)
DTaP
2) 6 wk 4 wk 4 wk 6 mo 6 mo
2)
IPV
3) 6 wk 4 wk 4 wk 6 mo
3)
Hib
4) 6 wk 4 wk if dose 1 was administered before 12 
mo of age
4 wk if current age is younger than 12 
mo
8 wk (as final dose) for children 
aged 12–59 mo who received 3 
doses before 12 mo of age
8 wk (as final dose) if dose 1 was admini-
stered at age 12–14 mo
8 wk (as final dose) if current age 
is 12 mo or older and dose 1 was 
administered before 12 mo of age and 
dose 2 was administered before 15 
mo of age
No further doses are needed if dose 1 was 
administered at age 15 mo or older
No further doses are needed if previous 
dose was administered at age 15 mo 
or older
PCV
5) 6 wk 4 wk if dose 1 was administered before 
12 mo of age and current age is younger 
than 24 mo
4 wk if current age is younger than 12 
mo
8 wk (as final dose) for children 
aged 12–59 mo who received 3 
doses before 12 mo of age
8 wk (as final dose) if dose 1 was admini-
stered at age 12 mo or older, or current 
age is 24–59 mo
8 wk (as final dose) if current age is 12 
mo or older
No further doses are needed if dose 1 was 
PCV13 and administered at age 24 mo or 
older
No further doses are needed if previous 
dose was administered at age 24 mo 
or older
8 wk (as final dose) if dose 1 was PCV10 
and administered at age 24 mo or older
RV
6) 6 wk 4 wk 4 wk
MMR
7) 12 mo 4 wk
Var
8) 12 mo 3 mo
JEV
9) 12 mo 7 days if IJEV is used; 12 months (as final 
dose) if LAJEV is used
6 mo 2 yr 5 yr
HepA
10) 12 mo 6 mo
Children and adolescents aged 7 yr or older who start late or who are more than 1 mo behind
HepB Birth 4 wk 8 wk and at least 16 wk after dose 1
1)
Tdap/Td
11) 7 yr 4 wk 4 wk if dose 1 was administered before 
12 mo of age
6 mo if dose 1 was administered 
before 12 mo of age
6 mo if dose 1 was administered at age 
12 mo or older
10 yr if dose 1 was administered 
at age 12 mo or older
IPV 6 wk 4 wk 4 wk 6 mo
MMR 12 mo 4 wk
Var 12 mo 4 wk if dose 1 was administered at 13 yr 
and older
JEV 12 mo 7 days if IJEV is used; 12 mo (as final dose) 
if LAJEV is used 
6 mo 2 yr
HepA 12 mo 6 mo
HPV
12) 9 yr Routine dosing interval Routine dosing interval
HepB, hepatitis B vaccine; DTaP, diphtheria and tetanus toxoids and acellular pertussis vaccine; IPV, inactivated polio vaccine; Hib, Haemophilus influenzae type b 
vaccine; PCV, pneumococcal conjugate vaccine; RV, rotavirus vaccine; MMR, measles, mumps, and rubella vaccine; Var, varicella vaccine; JEV, Japanese encephalitis 
vaccine; HepA, hepatitis A vaccine; Tdap, tetanus and diphtheria toxoids and acellular pertussis vaccine; HPV, human papilloma virus vaccine.
  1)HepB: Administer a complete series of HepB to persons who have no history of HepB immunization. The third dose should be administered no earlier than age of   
24 weeks, and at least 16 weeks after the first dose.
  2)DTaP: The fifth dose is not required if the fourth dose was administered at age 4 years or older. http://dx.doi.org/10.3345/kjp.2013.56.6.231
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  3)IPV: Before the age of 6 months, routine dosing interval is generally recommended, except for the infants who are at risk for imminent exposure to circulating 
poliovirus, only for whom minimum age and minimum intervals are recommended. Last dose should be administered no earlier than age of 4 years with an 
interval of 6 months or longer after the previous dose. The fourth dose is not required if the third dose was administered at age 4 years or older and at least 6 
months after dose 2. The fourth dose is required, however, if both oral polio vaccine and IPV were administered as part of the previous 3 doses.
  4)Hib: To children who received the first two doses with PRP-OMP before age 12 months, administer the third dose as final dose at age 12–15 months with a 
minimum interval of 8 weeks from the second dose. Hib is not routinely recommended for children at age 60 months or older. See Chapter 14. Haemophilus 
influenzae type b vaccine in the KPS Immunization Guideline, 2012 for further details.
5)PCV: PCV is not routinely recommended for children at age 60 months or older, except who have certain underlying medical conditions. See Chapter 15. 
Streptococcus pneumoniae vaccine in the KPS Immunization Guideline, 2012 for further details.
6)RV: The first dose of RV should be administered no later than 14 weeks 6 days, i.e., the vaccination should not be initiated for infants at age 15 weeks 0 days or 
older. The final dose should be administered no later than 8 months 0 days.
7)MMR: The second dose is routinely administered at age 4–6 years. If needed, however, it may be administered before age 4 years with an interval 4 weeks or 
more from the first dose.
8)Var: Administer all children a single dose of Var at age 12–15 months. Second dose of Var may be administered to children aged 15 months through 12 years 
who attend day-care centers, schools, or facilities where chickenpox is prevalent, provided at least 3 months have elapsed since the first dose. For adolescents 
aged 13 and older without evidence of immunity, two doses of Var are indicated with a minimum interval of 4 weeks.
9)JEV: If the third dose of inactivated JEV (IJEV) was administered at age 4–9 years, administer the fourth dose as the final dose at age 12 years or older. Fifth dose 
is not required if the third dose and fourth dose were administered at age 10 years or older. If LAJEV is used, administer 2 doses with a minimum interval of 12 
months.
10)HepA: Administer 2 doses with an interval of 6–18 months according to the instruction of each HepA product.
11)Tdap/Td: Previous DTaP doses can count as Tdap/Td doses. Children aged 7 years or older who have not completed DTaP series should receive Tdap/Td for 
catch-up immunization starting with Tdap.
12)HPV: Administer either series of Cervarix (GSK) or Gardasil (MSD) to females aged 13–18 years who have not previously been vaccinated. Administer the second 
dose one month (Cervarix) or two months (Gardasil) after the first dose and the third dose 6 months after the first dose for both vaccines.